INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 277 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $849,481 | -34.0% | 12,403 | -33.4% | 0.12% | -26.8% |
Q1 2024 | $1,288,020 | +61.5% | 18,613 | +67.2% | 0.16% | +5.8% |
Q4 2023 | $797,345 | +521.0% | 11,133 | +351.6% | 0.16% | +318.9% |
Q3 2023 | $128,402 | +61.2% | 2,465 | +95.9% | 0.04% | +48.0% |
Q2 2023 | $79,657 | +14.7% | 1,258 | -1.9% | 0.02% | +4.2% |
Q1 2023 | $69,474 | +36.5% | 1,283 | +33.4% | 0.02% | +20.0% |
Q4 2022 | $50,909 | +24.2% | 962 | +8.8% | 0.02% | +17.6% |
Q3 2022 | $41,000 | – | 884 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 360,000 | $11,502,000 | 2.65% |
Redmile Group, LLC | 610,171 | $19,495,000 | 1.60% |
Pier Capital, LLC | 257,256 | $8,219,000 | 1.18% |
WALL STREET ASSOCIATES | 358,857 | $11,465,000 | 1.08% |
SENZAR ASSET MANAGEMENT, LLC | 161,300 | $5,154,000 | 0.88% |
Rhenman & Partners Asset Management AB | 206,000 | $6,582,000 | 0.79% |
EAM Investors, LLC | 152,389 | $4,869,000 | 0.57% |
EDMOND DE ROTHSCHILD (SUISSE) S.A. | 50,000 | $1,598,000 | 0.51% |
Visium Asset Management, LP | 1,051,479 | $33,595,000 | 0.48% |
SPHERA FUNDS MANAGEMENT LTD. | 128,000 | $4,090,000 | 0.40% |